Anthony Quinn cements Aeglea CEO spot; Human Longevity bumps David Karow up to the top
→ After proving himself in one year as interim CEO at Aeglea BioTherapeutics $AGLE, Anthony Quinn is officially taking on the post permanently. Since he joined the Austin-based company as a board member in 2016, he’s seen it through an IPO and initiation of several Phase I trials for its rare disease drug, AEB1102. A former professor at Barts and the London School of Medicine, Quinn previously worked as CMO at Synageva Biopharma until Alexion came along to snap it up. He will be helped at the helm by Brian Lawlis, Itero founder and ex-CEO, who’s just been appointed to the board.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.